Back to Peptides

Cardiogen

Cardiovascular & Vascular Support

Cardiogen is a synthetic peptide shown to enhance cardiac regeneration, vascular perfusion, and myocardial bioenergetics. Originally developed to support heart recovery post-infarction, it is now studied for broader cardiometabolic and vascular applications in aging and disease. It acts by modulating endothelial and cardiac signaling at the cellular level.

Reconstitute
3 mL BAC + 20mg vial
67 mcg/unit
Daily Range
50–150 mcg Subcutaneous (SQ)
Daily
Standard Dose
100 mcg
Cycle
4–8 weeks
then reassess
Cardiogencardiac peptideheart regenerationmyocardial repairvascular health

Dosing & Reconstitution Guide

In preclinical models, Cardiogen has been administered at 100–200 μg per day for 10–15 days via subcutaneous injection. These findings are investigational and not applicable to human dosing..

Standard / Gradual Approach

20mg Vialstandard
PhaseDoseVolume
Weeks 1–2200 mcg3 units (0.03 mL)
Weeks 3–4300 mcg4.5 units (0.045 mL)
Week 5400 mcg6 units (0.06 mL)
Weeks 6–12500 mcg7.5 units (0.075 mL)

Protocol Summary

Subcutaneous (SQ): Daily · Dose range 50–150 mcg with gradual titration
Intramuscular (IM): Weekly · Dose range 50–150 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Administer daily for 4–8 weeks in cardiac recovery protocols. Pause for 2–4 weeks before restarting.

IM

Inject once weekly for 8 weeks. Typically used in chronic heart failure or post-MI rehabilitation cycles.

🧪 Quick Start

Vial Size
20 mg
BAC Water
3 mL
Concentration
6.67 mcg/unit
Starting Dose
200 mcg (3 units (0.03 mL))
Maintenance Dose
500 mcg (7.5 units (0.075 mL))

Potential Benefits & Use Cases

Cardiogen is a research-use-only peptide. It is not approved for human or veterinary use. All content is for educational and scientific reference based on preclinical data.
Demonstrates cardioprotective effects in rodent myocardial infarction models, reducing mortality and necrotic tissue (preclinical)
Stimulates cardiomyocyte and fibroblast proliferation while decreasing pro-apoptotic factors (preclinical)
Shows selective dual action: protects healthy cells while promoting apoptosis in tumor cells (preclinical)
Activates synthesis of actin, vimentin, tubulin, and nuclear matrix proteins (preclinical)
Clinical data Strong preclinical Limited data

Mechanism of Action

→Stimulates cardiomyocyte regeneration and mitochondrial recovery
→Enhances angiogenesis via VEGF signaling in cardiac tissue
→Inhibits cardiac fibrosis by modulating TGF-β and inflammatory cytokines
→Improves endothelial function and nitric oxide (NO) production in vasculature

Lifestyle & Optimization

timing

Consistent injection timing. Split into sterile aliquots for extended use.

diet

Heart-healthy diet. Document observable effects.

exercise

Moderate cardiovascular exercise as tolerated.

sleep

Ensure cold-chain storage. Adequate rest for cardiovascular recovery.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
MDPI Cells Journal (2023) — Senescence‑Associated Secretory Phenotype of Cardiovascular System Cells and InflammagingReference
MDPI International Journal of Molecular Sciences — Peptide Regulation of Gene Expression: A Systematic ReviewReference
PubMed — Tetrapeptide H‑Ala‑Glu‑Asp‑Arg‑OH stimulates expression of cytoskeletal and nuclear matrix proteinsReference
PubMed — Tumor‑modifying effect of cardiogen peptide on M‑1 sarcoma in senescent ratsReference
PubMed — Peptide bioregulators: experimental and clinical studies of geroprotective agentsReference
PubMed — Peptides and ageing: molecular mechanisms of peptide bioregulationReference
MDPI Molecules Journal — Molecular Mechanisms of Peptide Bioregulators and their Role in AgingReference
PubMed — Tissue‑Specific Peptide Bioregulators: Mechanisms and Clinical ApplicationsReference
PubMed Central — Short Peptides: Fundamental and Applied AspectsReference
PubMed — Peptide regulation of gene expression: A comprehensive overviewReference
PubMed — Cardiac peptides: mechanisms of cardioprotective actionReference
Tocris Bioscience — Peptide Stability and Storage GuidelinesReference

Side Effects & Safety

Common Side Effects

• Mild fatigue, temporary blood pressure fluctuation (user-reported)
• Minor stomach discomfort with oral form (user-reported)

🧮 Dose Calculator

Concentration
66.7
mcg/unit
Draw Volume
7
units (0.070 mL)
For a 500 mcg dose, draw 7 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
Moderate to high systemic uptake with efficient cardiac targeting via circulation
Oral Administration
Very low bioavailability
Half-Life
Approximately 4 hours
Degradation
Metabolized via hepatic and renal pathways
Tissue Specificity
Selective for myocardium, vascular endothelium, and pericardial tissues
⚗️

Peptide Details

Molecular Weight
1115.32
Formula
C50H74N16O15
Sequence
AKGSPQKSDNKD
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaApproved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 2–4 weeks with bacteriostatic water; avoid freeze–thaw cycles